1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Asymchem Laboratories (Tianjin) Co., Ltd.

Asymchem Laboratories (Tianjin) Co., Ltd.

6821.HK
Asymchem Laboratories (Tianjin) Co., Ltd.HK flagHong Kong Stock Exchange
121.90
HKD
+6.60
- -
43.98BMarket Cap
Asymchem Laboratories (Tianjin) Co., Ltd.
6821.HK
(Hong Kong Stock Exchange)

Recent

price

121.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.62
1.69
2.15
2.84
3.3
4.3
4.5
5.75
7.68
9.66
13.67
28.02
21.59
16.45
18.61
15.15
Revenue per Share
0.26
0.24
0.3
0.4
0.61
0.99
1.08
1.34
1.73
2.21
3.15
9.02
6.26
2.69
3.16
2.56
Basic EPS, GAAP
-0.44
-0.39
0.06
0.24
0.53
0.16
-0.34
-0.4
0.28
-1.37
-4.56
3.1
6.37
0.35
0.38
-2.83
Free Cash Flow per Basic Share
0.12
0.03
0.03
0.06
0.09
0.14
0.19
0.25
0.29
0.36
0.45
0.6
1.83
1.82
1.1
- -
Dividend per Share
0.56
0.88
1.15
1.52
2.04
2.91
3.6
4.65
6.02
7.74
10.11
17.83
22.43
23.94
25.6
26.17
Book Value per Share
2.06
2.31
2.51
2.9
3.47
6.9
6.6
7.5
9.12
17.36
35.62
41.19
46.62
46.17
47.65
48.02
Tangible Book Value per Share
251
252
252
252
251
256
316
319
320
326
339
366
362
353
358
362
Basic Weighted Avg Shares
406
424
543
716
831
1,103
1,423
1,835
2,460
3,150
4,639
10,255
7,825
5,805
6,670
5,489
Sales/Revenue/Turnover
20.78
17.42
18.1
18.12
21.66
26.97
34
24.64
26.11
28.29
25.34
30.93
29.33
12.1
18.8
21.78
Operating Margin (%)
21
30
40
48
53
63
75
103
122
157
214
342
464
503
551
- -
Depreciation Expense
65
60
75
102
154
253
341
428
554
722
1,069
3,302
2,269
949
1,133
928
Net Income, GAAP
15.38
14.82
15.9
14.19
14.95
15.32
14.7
11.76
11.18
11.33
10.37
11.55
11.98
12.74
12.42
12.23
Effective Tax Rate (%)
16.11
14.2
13.77
14.21
18.49
22.91
23.98
23.34
22.51
22.93
23.05
32.19
28.99
16.35
16.98
16.9
Profit Margin (%)
246
196
263
349
430
1,141
1,241
1,155
1,135
3,102
8,106
9,683
10,551
9,341
9,538
9,670
Working Capital
23
12
20
20
- -
- -
- -
- -
- -
26
46
110
106
283
256
239
LT Debt
542
608
686
785
937
1,833
2,155
2,511
3,046
5,990
12,610
15,695
17,510
16,863
17,646
17,962
Total Equity
- -
9.7
11.52
13.63
16.13
16.58
19.74
17.14
20.65
17.49
11.06
19.42
12.07
3.52
6.26
5.84
Return on Invested Capital (%)
- -
17.89
18.54
20.65
24.38
28.39
28.82
33.2
32.51
32.25
33.46
62.73
30.52
11.35
12.58
9.95
Return on Capital (%)
- -
33.33
29.24
30.33
34.3
40.18
36.23
32.67
32.47
32.43
35.9
66.31
30.96
11.45
12.85
10.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
53
54
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
256
239
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
361
361
Market Capitalization
33,114
23,478
29,010

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
11,506
11,731
Cash, Cash Equivalents & STI
- -
7,438
7,778
Accounts Receivable, Net
- -
1,946
1,845
Inventories
- -
1,471
1,621
Total Current Liabilities
- -
1,968
2,061
Payables & Accruals
- -
- -
- -
ST Debt
- -
53
54
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
39.52%
29.5%
4.65%
Free Cash Flow
-107.62%
18.49%
10.37%
Net Income, GAAP
37.16%
37.35%
19.35%
Sales/Revenue/Turnover
28.66%
26.75%
14.91%
Total Cash Common Dividend
43.69%
46.9%
-38.46%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,400
1,298
1,443
1,664
5,805
2025
1,541
1,647
- -
2,040
6,670
2026
1,802
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.76
- -
- -
- -
2.69
2025
0.89
- -
- -
- -
3.16
2026
0.84
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.82
2025
- -
- -
- -
- -
1.1
2026
- -
- -
- -
- -
- -
Similar Companies
Shanghai ZJ Bio-Tech Co., Ltd. (688317.SS)
Avecho Biotechnology Limited (AVEFF)
CalciMedica, Inc. (CALC)
CohBar, Inc. (CWBR)
Intensity Therapeutics, Inc. (INTS)
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
Business
Asymchem Laboratories (Tianjin) Co., Ltd. Asymchem Laboratories (Tianjin) Co., Ltd. is a China-based contract development and manufacturing organization (CDMO) that provides one-stop comprehensive services for pharmaceutical outsourcing across the drug development lifecycle; its core offerings encompass customized research, development, and production of small molecule drugs including process development, optimization, analytical services, scale-up, and ton-scale manufacturing of registered starting materials, advanced intermediates, and active pharmaceutical ingredients (APIs); chemical macromolecule CDMO solutions for peptides, oligonucleotides, glycans, and toxins-linkers; biological macromolecule CDMO for monoclonal antibodies, antibody-drug conjugates, and messenger RNA; formulation CDMO with pre-formulation, solid form selection, polymorph screening, parenteral and oral solid dosage development, and commercial-scale production; clinical research organization (CRO) services; synthetic biology and technology output; as well as pharmaceutical analysis, testing, medical R&D, drug product manufacturing, raw material development, import-export trade, and information technology support. The company operates globally with facilities in Mainland China including its headquarters in Tianjin Economic-Technological Development Zone, established in 1998, alongside sites in the United States in North Carolina, Massachusetts, and international locations such as Shanghai and its first European manufacturing base in Sandwich, UK; it serves leading multinational pharmaceutical and biotechnology firms targeting pre-clinical, clinical, and commercial stages in domestic Chinese and foreign markets. Recently, Asymchem expanded into Europe by acquiring the former Pfizer UK small molecule API pilot plant and development laboratories in Sandwich, Kent, through a lease agreement, with operations commencing in mid-2024, adding capabilities for peptides, oligonucleotides, continuous flow, and biocatalysis while planning to employ around 100 staff; this follows prior investments in Tianjin facilities and listings on the Shenzhen Stock Exchange (002821.SZ) in 2018 and Hong Kong Stock Exchange (6821.HK), enhancing its global supply chain and sustainability initiatives in the CDMO sector.